Market Overview:
The global palbociclib market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of breast cancer, rising awareness about palbociclib as a treatment for breast cancer, and increasing approvals for palbociclib by regulatory authorities. Based on type, the global palbociclib market can be segmented into 75mg tablets, 100mg tablets, and 125mg tablets. The 100mg tablet segment is expected to account for the largest share of the global palbociclib market in 2018. This segment is also projected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. Based on application, the global palbociclib market can be divided into estrogen receptor positive (ER+) breast cancer, HER2 negative (HER2-) advanced breast cancer, metastatic breast cancer, and other applications.
Product Definition:
A kinase inhibitor used to treat estrogen receptor-positive breast cancer. Palbociclib is a pill that is taken once a day.
75mg Tablets:
75mg tablets is used for the treatment of breast cancer. It works by blocking some of the hormones that stimulate or grow cancer. Hormones such as oestrogen, progesterone and testosterone are responsible for growth & development in all body parts including breasts, lungs, brain etc.
75 mg tablet is one of the most prescribed medicines to women with breast cancer across U.
100mg Tablets:
100mg Tablets is used for the treatment of breast cancer. It is also used in combination with other medicines to treat advanced prostate cancer and multiple myeloma. The medicine works by blocking some of the enzymes that cause cell growth.
The U.S Food and Drug Administration (FDA) has approved this drug for sale in the U.S.
Application Insights:
The estrogen receptor positive breast cancer segment dominated the global market in 2017 and is expected to maintain its lead over the forecast period. This can be attributed to increasing awareness about early detection among women, resulting in a growing number of diagnosed cases. In addition, factors such as rising income levels across various regions and changing lifestyles have led to an increase in the incidence of this disease.
The other application segment includes non-metastatic breast cancer and metastatic breast cancer which together accounted for a share of 15% in 2017 owing to their high unmet medical needs. Palbociclib is approved by FDA for use against metastatic Breast Cancer (MBC) which has spread from the original site after treatment at another location was carried out unsuccessfully or there was no response after 2 courses of first line therapy drugs at another site.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, high adoption of Palbociclib and rising awareness about early diagnosis among women population in this region. In addition, favorable reimbursement policies for patients are also expected to drive growth over the forecast period. Asia Pacific is expected to witness lucrative growth during the forecast period owing to increasing number of approvals by regulatory agencies such as China Food and Drug Administration (CFDA) and Japan Ministry of Health, Labor & Welfare (MHLW). Moreover, growing healthcare expenditure coupled with availability of affordable treatment options is further anticipated fuel regional demand during the forecast period.
In October 2016; Pfizer Inc., a U.S.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the palbociclib market. According to a study by the World Health Organization (WHO), an estimated 14 million new cases of cancer were diagnosed in 2012, and this number is expected to rise to 24 million by 2035. This will create a large pool of patients who will require treatment, thereby driving the demand for palbociclib.
- Rising awareness about early detection and treatment: There is an increasing awareness among people about the importance of early detection and treatment of cancer. This has led to an increase in demand for palbociclib, as it offers better outcomes when used in combination with other therapies at an early stage of disease progression.
- Growing preference for targeted therapies: The growing preference for targeted therapies over traditional chemotherapy regimens is another key growth driver for the palbociclib market. Palbociclib targets specific proteins that are overexpressed in breast cancers, leading to fewer side effects as compared to traditional chemotherapies that affect all cells indiscriminately.
Scope Of The Report
Report Attributes
Report Details
Report Title
Palbociclib Market Research Report
By Type
75mg Tablets, 100mg Tablets, 125mg Tablets
By Application
Estrogen Receptor Positive (ER+) Breast Bancer, HER2 Negative (HER2-) Advanced Breast Cancer, Metastatic Breast Cancer, Other
By Companies
Pfizer, Beacon Pharmaceuticals, Incepta Pharmaceuticals, Pharmaceuticals, Bluepharma, NANO DARU
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
248
Number of Tables & Figures
174
Customization Available
Yes, the report can be customized as per your need.
Global Palbociclib Market Report Segments:
The global Palbociclib market is segmented on the basis of:
Types
75mg Tablets, 100mg Tablets, 125mg Tablets
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Estrogen Receptor Positive (ER+) Breast Bancer, HER2 Negative (HER2-) Advanced Breast Cancer, Metastatic Breast Cancer, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Beacon Pharmaceuticals
- Incepta Pharmaceuticals
- Pharmaceuticals
- Bluepharma
- NANO DARU
Highlights of The Palbociclib Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 75mg Tablets
- 100mg Tablets
- 125mg Tablets
- By Application:
- Estrogen Receptor Positive (ER+) Breast Bancer
- HER2 Negative (HER2-) Advanced Breast Cancer
- Metastatic Breast Cancer
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Palbociclib Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Palbociclib is a drug that is used to treat breast cancer. It works by blocking the growth of cancer cells.
Some of the major players in the palbociclib market are Pfizer, Beacon Pharmaceuticals, Incepta Pharmaceuticals, Pharmaceuticals, Bluepharma, NANO DARU.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Palbociclib Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Palbociclib Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Palbociclib Market - Supply Chain
4.5. Global Palbociclib Market Forecast
4.5.1. Palbociclib Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Palbociclib Market Size (000 Units) and Y-o-Y Growth
4.5.3. Palbociclib Market Absolute $ Opportunity
5. Global Palbociclib Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Palbociclib Market Size and Volume Forecast by Type
5.3.1. 75mg Tablets
5.3.2. 100mg Tablets
5.3.3. 125mg Tablets
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Palbociclib Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Palbociclib Market Size and Volume Forecast by Application
6.3.1. Estrogen Receptor Positive (ER+) Breast Bancer
6.3.2. HER2 Negative (HER2-) Advanced Breast Cancer
6.3.3. Metastatic Breast Cancer
6.3.4. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Palbociclib Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Palbociclib Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Palbociclib Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Palbociclib Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Palbociclib Demand Share Forecast, 2019-2026
9. North America Palbociclib Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Palbociclib Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Palbociclib Market Size and Volume Forecast by Application
9.4.1. Estrogen Receptor Positive (ER+) Breast Bancer
9.4.2. HER2 Negative (HER2-) Advanced Breast Cancer
9.4.3. Metastatic Breast Cancer
9.4.4. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Palbociclib Market Size and Volume Forecast by Type
9.7.1. 75mg Tablets
9.7.2. 100mg Tablets
9.7.3. 125mg Tablets
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Palbociclib Demand Share Forecast, 2019-2026
10. Latin America Palbociclib Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Palbociclib Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Palbociclib Market Size and Volume Forecast by Application
10.4.1. Estrogen Receptor Positive (ER+) Breast Bancer
10.4.2. HER2 Negative (HER2-) Advanced Breast Cancer
10.4.3. Metastatic Breast Cancer
10.4.4. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Palbociclib Market Size and Volume Forecast by Type
10.7.1. 75mg Tablets
10.7.2. 100mg Tablets
10.7.3. 125mg Tablets
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Palbociclib Demand Share Forecast, 2019-2026
11. Europe Palbociclib Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Palbociclib Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Palbociclib Market Size and Volume Forecast by Application
11.4.1. Estrogen Receptor Positive (ER+) Breast Bancer
11.4.2. HER2 Negative (HER2-) Advanced Breast Cancer
11.4.3. Metastatic Breast Cancer
11.4.4. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Palbociclib Market Size and Volume Forecast by Type
11.7.1. 75mg Tablets
11.7.2. 100mg Tablets
11.7.3. 125mg Tablets
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Palbociclib Demand Share, 2019-2026
12. Asia Pacific Palbociclib Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Palbociclib Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Palbociclib Market Size and Volume Forecast by Application
12.4.1. Estrogen Receptor Positive (ER+) Breast Bancer
12.4.2. HER2 Negative (HER2-) Advanced Breast Cancer
12.4.3. Metastatic Breast Cancer
12.4.4. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Palbociclib Market Size and Volume Forecast by Type
12.7.1. 75mg Tablets
12.7.2. 100mg Tablets
12.7.3. 125mg Tablets
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Palbociclib Demand Share, 2019-2026
13. Middle East & Africa Palbociclib Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Palbociclib Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Palbociclib Market Size and Volume Forecast by Application
13.4.1. Estrogen Receptor Positive (ER+) Breast Bancer
13.4.2. HER2 Negative (HER2-) Advanced Breast Cancer
13.4.3. Metastatic Breast Cancer
13.4.4. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Palbociclib Market Size and Volume Forecast by Type
13.7.1. 75mg Tablets
13.7.2. 100mg Tablets
13.7.3. 125mg Tablets
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Palbociclib Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Palbociclib Market: Market Share Analysis
14.2. Palbociclib Distributors and Customers
14.3. Palbociclib Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Pfizer
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Beacon Pharmaceuticals
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Incepta Pharmaceuticals
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Pharmaceuticals
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Bluepharma
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. NANO DARU
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
